ARCA biopharma Inc. (ABIO)’s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR)

This is therefore a comparing of the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation in ARCA biopharma Inc. (NASDAQ:ABIO) and Neuralstem Inc. (NASDAQ:CUR). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ARCA biopharma Inc. N/A 0.00 7.93M -0.82 0.00
Neuralstem Inc. N/A 39.87 4.92M -0.52 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for ARCA biopharma Inc. and Neuralstem Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
ARCA biopharma Inc. 0.00% 0% 0%
Neuralstem Inc. 0.00% -123.1% -74.7%

Risk and Volatility

ARCA biopharma Inc.’s volatility measures that it’s 108.00% more volatile than Standard & Poor’s 500 due to its 2.08 beta. Competitively, Neuralstem Inc. is 162.00% more volatile than Standard & Poor’s 500, because of the 2.62 beta.

Liquidity

ARCA biopharma Inc. has a Current Ratio of 8.5 and a Quick Ratio of 8.5. Competitively, Neuralstem Inc.’s Current Ratio is 5.5 and has 5.5 Quick Ratio. ARCA biopharma Inc.’s better ability to pay short and long-term obligations than Neuralstem Inc.

Institutional and Insider Ownership

Roughly 15.4% of ARCA biopharma Inc. shares are owned by institutional investors while 16.8% of Neuralstem Inc. are owned by institutional investors. ARCA biopharma Inc.’s share owned by insiders are 0.89%. On the other hand, insiders owned about 13.52% of Neuralstem Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ARCA biopharma Inc. 5.75% 9.55% -15.6% -24.74% -36.11% 37.93%
Neuralstem Inc. 6.47% 16.4% 0.1% -58.3% -66.18% 59.85%

For the past year ARCA biopharma Inc. has weaker performance than Neuralstem Inc.

Summary

On 4 of the 7 factors Neuralstem Inc. beats ARCA biopharma Inc.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.